For Immediate Release
Chicago, IL – September 19, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Brinker International Inc.’s ( EAT- Free Report), DineEquity, Inc. ( DIN- Free Report), AFC Enterprises Inc. ( AFCE- Free Report), CEC Entertainment Inc. ( CEC- Free Report) and CONMED Corporation ( CNMD- Free Report)
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Wednesday’s Analyst Blog:
Brinker Partners with Ziosk
Dallas, Texas-based restaurateur Brinker International Inc.’s ( EAT- Free Report) subsidiary Chili’s Grill & Bar (Chili’s) recently partnered with Ziosk, the manufacturer of world’s first pay-at-the table, entertainment and easy-ordering solutions tablet especially designed for the restaurant sector. Per the deal, Chili’s will install Ziosk 7-inch tabletop tablets across all of its 823 company-owned restaurants in the U.S. by the first half of 2014.
The company has received impressive feedback for the experimental rollout of the device at some of its company-owned locations. Hence, it has decided to go ahead with the introduction of the Ziosk touch screen tablets at all its restaurants to boost guest satisfaction.
This tablet will allow the customers to easily choose food items from Chili’s wide range of menus. Also, the pay-on-demand facility will quicken bill payment. Apart from this, the Ziosk tablet will also offer several entertainment facilities such as video games, music and Facebook for the guests.
Another restaurateur, DineEquity, Inc. ( DIN- Free Report), has also brought Ziosk devices in its Applebee’s Neighborhood Grill and Bar (Applebee's) restaurants.
The use of technological devices is continuously increasing among consumers. In 2012, Technomic carried out a Consumer-Facing Technology Survey which found around 51% consumers voting for digital ordering. Thus, the launch of Ziosk will take Brinker a step forward in using technology-based services.
The partnership will help the Zacks Rank #3 (Hold) company drive traffic and sales through enhanced customer experience. These devices will improve the dining experience by making it customer friendly.
Other Stocks to Consider
Other players in the restaurant industry that look attractive at the current levels include AFC Enterprises Inc. ( AFCE- Free Report) and CEC Entertainment Inc. ( CEC- Free Report). Both these restaurateurs carry a Zacks Rank #2 (Buy).
CONMED Slips to Sell
On Sep 17, Zacks Investment Research downgraded CONMED Corporation ( CNMD- Free Report) to a Zacks Rank #4 (Sell) from Zacks Rank #3 (Hold).
Why the Downgrade?
CONMED witnessed downward estimate revisions following disappointing second-quarter 2013 results. The medical technologies and surgical devices company also provided a lower guidance for 2013.
On July 26, CONMED reported second-quarter adjusted earnings per share that remained flat year-over-year at 43 cents and missed the Zacks Consensus Estimate by 2 cents. Revenues dropped 1.7% (2.3% at constant exchange rate) to $193.0 million, reflecting a soft healthcare utilization and spending environment in the global economy. Revenues missed the Zacks Consensus Estimate by 1.5%.
Ongoing dismal macroeconomic conditions along with poor capital spending and sluggish volume/procedure growth are major causes of worry. Moreover, the company operates in a highly-competitive orthopedic surgery market against larger and more technically-competent companies. However, the only positive factor in the second quarter results was the company’s higher margins driven by leveraged operating efficiency and cost-saving initiatives undertaken by management.
CONMED lowered its guidance for 2013, owing to the difficult austerity measures persisting in Europe as well as flattish healthcare utilization rate in the U.S. The company narrowed its previous earnings guidance of $1.80-$1.90 per share to $1.80-$1.85 per share. The guidance assumes negative impact of the medical device excise tax and foreign exchange headwinds. Similarly, management also lowered its estimated 2013 sales forecast to $770 million–$775 million from the earlier prediction of $770 million–$780 million.
The Zacks Consensus Estimate for 2013 inched up 0.6% to $1.82 per share over the last 30 days. However, for 2014, the Zacks Consensus Estimate decreased by roughly 1% to $2.05 per share over the same period.
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on EAT - FREE
Get the full Report on DIN - FREE
Get the full Report on AFCE - FREE
Get the full Report on CEC - FREE
Get the full Report on CNMD - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.